Brussels, 18/10/2011 (Agence Europe) - A process that uses stem cells obtained from human embryos and which leads to the destruction of the latter cannot be patented. This exclusion from patenting does not only cover the use of human embryos for industrial and commercial purposes but also their use for scientific research. It can only be patented when it is used for therapeutic or diagnostic purposes applicable to the human embryo and beneficial to it.
This is the main thrust of an...